Lupus & antiphospholipid syndrome
Achievement of real-world adapted Definition of Remission In SLE (DORIS) remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study
Authors' conclusion
The probability of adapted DORIS remission in US patients initiating belimumab was similar to rates reported in observational studies outside the USA, supporting the real-world effectiveness of belimumab.
Study context
- Population
- US patients with systemic lupus erythematosus (SLE) initiating belimumab, OM1 PremiOM™ SLE dataset (2013–2024); most White, female, Southern USA, commercial insurance
- Participants
- 398 patients
- Outcome
- Probability of adapted DORIS remission: Clinician-recorded SLEDAI (crSLEDAI) or eSLEDAI = 0, Physician Global Assessment (PGA) <2 (0-10 NRS), prednisone-equivalent dose ≤5 mg/day
- Follow-up
- 28, 48 and 52 weeks post-treatment initiation
Methodological detailsobservational, electronic health records/healthcare claims data (2013-2024)
- Observational
- Electronic health records/healthcare claims data (2013-2024)
Main finding
As reported in the abstract
Adapted DORIS remission probability (Kaplan-Meier) · 52 weeks
Belimumab
28.3%
95% CI 19.8–35.9
Observational data: associations, not effects.
Further findings
Remission probability by subgroup (age ≥50 years, non-White, cr/estimated SLEDAI (eSLEDAI) ≤5)
- Older patients (≥50 years), non-White individuals and patients with cr/eSLEDAI ≤5 had slightly higher remission probabilities than their counterparts; estimates differed by censoring approach and confidence bounds overlapped
Predictors of remission (adjusted multivariable logistic regression)
- Increasing age, non-White race and cr/eSLEDAI ≤5 were significant predictors of remission
Original publication
Achievement of real-world adapted DORIS remission targets among patients with systemic lupus erythematosus initiating belimumab in the USA: A retrospective, observational, cohort study. Lupus. Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →